Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1993-05-17
1995-07-18
Cintins, Marianne M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
A61K 3119
Patent
active
054341850
ABSTRACT:
Aurintricarboxylic acid has potent anti-angiogenic activity and may be used for new therapeutic approaches for diseases of neovascularization including the treatment of solid tumors, diabetic retinopathy and arthritis, among others.
REFERENCES:
patent: 4007270 (1977-02-01), Bernstein et al.
patent: 4113879 (1978-09-01), Jones et al.
patent: 4749647 (1988-06-01), Thomas et al.
patent: 4880788 (1989-11-01), Moake et al.
patent: 5045467 (1991-09-01), Bertheussen
Benezra, Miriam, et al. "Reversal of Basic Fibroblast Growth Factor-mediated Autocrine Cell Transformation by Aromatic Anionic Compounds", Cancer Research, vol. 52, (Oct. 15, 1992) pp. 5656-5662.
Bouck, N. "Tumor Angiogenesis: The Role of Oncogenes and Tumor Suppressor Genes", Cancer Cells, vol. 2, No. 6, (Jun. 1990) pp. 179-185.
Cushman, M. et al. "Preparation and Anti-HIV Activities of Aurintricarboxylic Acid Fractions and Analogues: Direct Correlation of Antiviral Potency with Molecular Weight", J. Med. Chem., vol. 34, (1991) pp. 329-337.
Cushman, M. et al., "Synthesis and Anti-HIV Activities of Low Molecular Weight Aurinitricarboxylic Acid Fragments and Related Compounds", J. Med. Chem., vol. 34, (1991) pp. 337-342.
Folkman, J. et al., "Angiogenic Factors", Science, vol. 235, (1987) pp. 442-447.
Folkman, J. et al. "Angiogenesis Inhibition and Tumor Regression Caused by Heparin or a Heparin Fragment in the Presence of Cortisone", Science, vol. 221, (Aug. 19, 1983) pp. 719-725.
Gagliardi, A. et al. "Inhibition of Angiogenesis by Suramin", Cancer Research, vol. 52, (Sep. 15, 1992) pp. 5073-5075.
Gonzalez, R .G. et al. "Fractionation and Structural Elucidation of the Active Components of Aurintricarboxylic Acid, a Potent Inhibtior of Protein Nucleic Acid Interactions". Biochimica et Biophysica Acta, vol. 562, (1979) pp. 534-545.
Kan, M. et al. "An Essential Heparin-binding Domain in the Fibroblast Growth Factor Receptor Kinase", Science, vol. 259, (Mar. 26, 1993) pp. 1918-1921.
Klagsbrun, M. et al. "Minireview: A Dual Receptor System is Required for Basic Fibroblast Growth Factor Activity", Cell, pp. 229-231 (1991).
Mellon, W. S. "Inhibitory Action of Aurintricarboxylic Acid and Rifamycin AF/013 at the Polynucleotide Domain of 1,25-Dihydroxyvitamin D.sub.3 -Receptor Complexes", Biochemical Pharmacology, vol. 33, No. 7, (1984) pp. 1047-1057.
Moudgil, V. K. et al. "Modulation of DNA Binding of Glucocorticoid Receptor by Aurintricarboxylic Acid", J. Steroid Biochem., vol. 23, No. 2, (1985) pp. 125-132.
Nakane, H. et al. "Differential Inhibition of various Deoxyribonucleic Acid Polymerases by Evans Blue and Aurintricarboxylic Acid", Eur. J. Biochem., vol. 177, (1988) pp. 91-96.
Oikawa, T. et al. "A Highly Potent Antiangiogenic Activity of Retinoids", Cancer Letters, vol. 48, (1989) pp. 157-162.
Ornitz, D. M. et al. "Heparin is Required for Cell-free Binding of basic Fibroblast Growth Factor to a Soluble Receptor and for Mitogenesis in Whole Cells", Molecular and Cellular Biology, vol. 12, (Jan. 1992) pp. 240-247.
Risaue, W. "Angiogenic Growth Factors", Progress in Growth Factor Research, vol. 2, (1990) pp. 71-79.
Schols, D. et al. "Specific Interaction of Aurinitricarboxylic Acid with the Human Immunodeficiency Virus/CD4 Cell Receptor", Proc. Natl. Acad. Sci. USA, vol. 86, (May 1989) pp. 3322-3326.
Skidmore, A. F. et al. "Characterization and Use of the Potent Ribonuclease Inhibitor Aurintricarboxylic acid for the Isolation of RNA from Animal Tissues", Biochem. J., vol. 263, (1989) pp. 73-80.
Strony, J. et al. "Autrinicarboxylic Acid in a Canine Model of Coronary Artery Thrombosis", Circulation, vol. 81, No. 3, (Mar. 1990) pp. 1106-1114.
Weisz, P. B. et al. "Angiogenesis and Heparin Mimics", Angiogenesis Key Principles--Science--Technology--Medicine, (eds. R. Steiner, P. B. Weisz & R. Langer), (1992) pp. 107-117.
Woltering, E. A. et al. "Somatostatin Analogues Inhibit Angiogenesis in the Chick Chorioallantoic Membrane", Journal of Surgical Research, vol. 50 (1991) pp. 245-251.
The Merck Index, (1989) .sctn.899 p. 140.
The Merck Index, (1989) .sctn.4571 p. 735.
The Merck Index, (1989) .sctn.8986 p. 1423.
Takigawa, M. et al. "Tumor Angiogenesis and Polyamines: .alpha.-Difluoromethylornthine, an Irreversible Inhibitor of Ornithine Decarboxylase, Inhibitors B16 Melanoma-induced Angiogenesis in Ovo and the Proliferation of Vascular Endothelial Cells in Vitro", Cancer Research, vol. 50, (Jul. 1, 1990) pp. 4131-4138.
Bhattacharyya Anjan
Collins Delwood C.
Gagliardi Antonio
Cintins Marianne M.
The University of Kentucky Research Foundation
Weddington K.
LandOfFree
Method for inhibiting angiogenesis with aurintricarboxylic acid, does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for inhibiting angiogenesis with aurintricarboxylic acid,, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for inhibiting angiogenesis with aurintricarboxylic acid, will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2419153